Valuation: Mylan N.V.

Market Cap 20.45B 17.78B 16.55B 15.19B 28.69B 1,952B 29.13B 195B 76.55B 972B 76.8B 75.11B 3,259B P/E 2026 *
77.3x
P/E 2027 * 32.7x
Enterprise Value 32.64B 28.37B 26.41B 24.25B 45.79B 3,116B 46.5B 311B 122B 1,551B 123B 120B 5,201B EV / Sales 2026 *
2.21x
EV / Sales 2027 * 2.1x
Free-Float
92.23%
Yield 2026 *
2.9%
Yield 2027 * 2.97%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+2.66% - - 20.45B
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
Average -1.14%-1.20%+29.13%+50.05% 397.08B
Weighted average by Cap. -0.98%-1.93%+37.18%+73.22%

Financials

2026 *2027 *
Net sales 14.78B 12.85B 11.96B 10.98B 20.74B 1,411B 21.06B 141B 55.33B 702B 55.51B 54.29B 2,355B 15.04B 13.07B 12.17B 11.17B 21.1B 1,436B 21.43B 143B 56.3B 715B 56.48B 55.24B 2,397B
Net income 3.05M 2.65M 2.47M 2.27M 4.28M 291M 4.35M 29.11M 11.42M 145M 11.46M 11.21M 486M 339M 294M 274M 252M 475M 32.34B 483M 3.23B 1.27B 16.1B 1.27B 1.24B 53.98B
Net Debt 12.19B 10.6B 9.86B 9.05B 17.1B 1,164B 17.36B 116B 45.62B 579B 45.78B 44.77B 1,942B 11.2B 9.73B 9.06B 8.32B 15.71B 1,069B 15.95B 107B 41.91B 532B 42.05B 41.12B 1,784B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-